Monkeypox: A Viral Zoonotic Disease of Rising Global Concern

A recent increase in globally reported cases of monkeypox (mpox) has been detected, making it a public health emergency of international concern. The virus, which is endemic to Central and West Africa, was initially thought to be spread primarily through animal contact, but recent outbreaks have highlighted the potential for human-to-human transmission, particularly among men who have sex with men. The virus causes a rare and potentially life-threatening disease, with limited antiviral treatments and vaccines available. Researchers from Hamad Medical Corporation are calling for further investigation into the virus's animal reservoir, viral mutations, and optimal diagnostics, as well as the development of more effective treatments and vaccines.

Key Takeaways:

• The current outbreak of mpox has resulted in an increase in globally reported confirmed cases and deaths, making it a public health emergency of international concern.
• The virus is spread primarily through close, intimate contact, especially among men who have sex with men, and is usually a self-limited disease.
• Limited approved antiviral treatments, such as tecovirimat, are available, but their widespread availability and effectiveness in the current outbreak remain to be investigated.
• Public health control measures include surveillance, case identification, contact tracing, and targeted vaccination of contacts at high risk of exposure.
• Critical knowledge gaps in understanding mpox include the animal reservoir(s) responsible for initial spillover events, viral mutations that may enhance transmissibility, optimal diagnostics for noninvasive specimens, effective antiviral therapies, next-generation vaccines providing longer-term immunity, and building global capacity for outbreak response.
• The development of more effective treatments and vaccines is essential to containing the outbreak and preventing future global emergence of mpox.
• Research has highlighted the need for ongoing investigation and research into the evolving epidemiology, pathogenicity, transmissibility, and ecology of mpox.

Notable Figures:

• Sukumaran Anil, Betsy Joseph, Vishnupriya K. Sweety, Nandita Suresh, Tumos Waltimo, and Mary Thomas contributed to the research on mpox.
• Anil has an ORCID ID of 0000-0002-6440-8780.

Statistics:

• The number of globally reported confirmed cases of mpox has increased in 2024.
• The virus causes a rare and potentially life-threatening disease, with a mortality rate of X percent (no specific data provided).
• Only X number of antiviral treatments, such as tecovirimat, have been approved for the treatment of mpox (no specific data provided).
• The widespread availability and effectiveness of tecovirimat in the current outbreak remain to be investigated.

Sources:

• Monkeypox: A Viral Zoonotic Disease of Rising Global Concern. Infectious Diseases & Immunity, 2024,4(3). DOI: 10.1097/id9.0000000000000124
• NewsRx. Hamad Medical Corporation Researcher Describes Research in Monkeypox (Monkeypox: A Viral Zoonotic Disease of Rising Global Concern). Vaccine Weekly. August 7, 2024; p 2483.